Shares of Entest BioMedical Inc. (PINK: ENTB), a company engaged in the development of stem cell therapy treatments for chronic obstructive pulmonary disease, are soaring in trading today.
At last check, ENTB shares were trading 48.81% higher at $0.0125 on above average volume of 22.03 million. The stock has now gained more than 160% in the last three trading sessions.
According to a filing made by ENTB earlier this month, the company entered into an Equity Purchase Agreement with Southridge Partners II LP.
As per the terms of the agreement, Southridge will purchase at ENTB’s election up to $10 million of ENTB’s registered common stock.
Recent Comments